Search

Keywords: Pfizer COVID-19 vaccine; SARS-CoV-2; S-RBD-specific; immunoglobulins; seroconversion; decreasing immunity; neutralizing antibodies EN Pfizer COVID-19 vaccine SARS-CoV-2 S-RBD-specific immunoglobulins seroconversion decreasing immunity neutralizing antibodies 1 3 3 01/05/22 20211201 NES 211201 Research letter Emerging evidence is offering significant insights into the effectiveness and safety of the vaccination against the Coronavirus Disease 2019 (COVID-19), but another crucial aspect of the current global vaccination campaign is the time trend of the antibody response to COVID-19 vaccines over a longer period and the resulting duration of the protection offered.1 Here, we present data on the dynamics of antibodies that bind SARS-CoV-2 spike (S) protein receptor binding domain (RBD) - the most critical target for SARS-CoV-2-specific antibodies within the S1 sub-unit2 - after 6 months from the administration with BNT162b2 vaccine. Pfizer COVID-19 vaccine, SARS-CoV-2, S-RBD-specific, immunoglobulins, seroconversion, decreasing immunity, neutralizing antibodies Complete methods of the VASCO project have been presented elsewhere.3 In this survey, HCWs who were administered the two-dose BNT162b2 mRNA vaccine 21 days apart between December 2020 and January 2021 were invited to undertake a quantitative serology test for the research of SARS-CoV-2 S-RBD-specific immunoglobulins G (IgG). [Extracted from the article]